5 Great Valley Parkway
56 articles with Promedior
LEXINGTON, Mass. , Feb. 13, 2020 /PRNewswire/ -- Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an up
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior
Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced positive safety and efficacy data from a Phase 2 study of PRM-151 in myelofibrosis (MF) patients that either failed (76%) or were ineligible for Ruxolitinib.
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
Promedior, Inc today announced that positive safety and efficacy data from the Company's open-label extension study of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF) were simultaneously published in The Lancet Respiratory Medicine and presented at the American Thoracic Society 2019 International Conference
Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
Promedior, Inc. announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for Idiopathic Pulmonary Fibrosis.
Promedior Announces Pivotal Path for PRM-151 in Idiopathic Pulmonary Fibrosis Following Positive End-of-Phase 2 Meeting with FDA
Promedior, Inc., announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF)
Exec Who Orchestrated Promedior's $1.25 Billion Buyout Deal From Bristol-Myers Squibb To Helm Proclara
Promedior Announces Completion Of Patient Enrollment Milestones In Phase 2 Clinical Studies Of PRM-151 In Both Idiopathic Pulmonary Fibrosis And Myelofibrosis
Promedior Presents Positive Phase II Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting
Promedior Announces Initiation Of A Phase II Clinical Study Of PRM-151 In Idiopathic Pulmonary Fibrosis (IPF)
Promedior Presents Additional Positive Phase 2 Data For PRM-151 In Myelofibrosis At EHA Annual Meeting
Promedior Announces Presentation Of Additional Positive Phase II Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of The European Hematology Association
Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting
Promedior Announces Presentation Of Retrospective Quantitative Imaging Analysis Of Phase 1b Data In Idiopathic Pulmonary Fibrosis